NewAmsterdam Pharma Company N.V.

DB:KH6 Stock Report

Market Cap: €2.4b

NewAmsterdam Pharma Valuation

Is KH6 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of KH6 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€128.28
Fair Value
87.2% undervalued intrinsic discount
8
Number of Analysts

Below Fair Value: KH6 (€16.4) is trading below our estimate of fair value (€128.28)

Significantly Below Fair Value: KH6 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for KH6?

Key metric: As KH6 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for KH6. This is calculated by dividing KH6's market cap by their current book value.
What is KH6's PB Ratio?
PB Ratio3.4x
BookUS$757.50m
Market CapUS$2.59b

Price to Book Ratio vs Peers

How does KH6's PB Ratio compare to its peers?

The above table shows the PB ratio for KH6 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
BIO3 Biotest
2.3x29.3%€1.4b
FYB Formycon
0.8x14.2%€468.8m
HPHA Heidelberg Pharma
3.4x-33.0%€121.2m
MDG1 Medigene
1.2x14.1%€23.8m
KH6 NewAmsterdam Pharma
3.4x45.1%€2.6b

Price-To-Book vs Peers: KH6 is expensive based on its Price-To-Book Ratio (3.4x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does KH6's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
KH6 3.4xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: KH6 is expensive based on its Price-To-Book Ratio (3.4x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is KH6's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

KH6 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate KH6's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst KH6 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€41.95
0%
12.5%€49.48€33.89n/a8
Mar ’26€16.40
€41.79
+154.8%
12.9%€49.48€34.02n/a9
Feb ’26€20.60
€42.68
+107.2%
12.0%€50.45€34.02n/a9
Jan ’26€24.00
€41.69
+73.7%
15.4%€50.45€27.95n/a9
Dec ’25€19.20
€36.70
+91.1%
17.9%€47.55€27.95n/a8
Nov ’25€15.00
€34.84
+132.3%
17.4%€46.20€27.10n/a8
Oct ’25€14.40
€34.73
+141.2%
17.5%€46.20€27.10n/a8
Sep ’25€14.40
€34.90
+142.3%
17.1%€46.20€27.44n/a8
Aug ’25€15.70
€35.40
+125.5%
17.6%€46.20€27.86n/a7
Jul ’25€17.00
€35.23
+107.2%
17.9%€46.62€27.86n/a7
Jun ’25€16.20
€32.18
+98.6%
14.7%€41.61€26.81n/a7
May ’25€19.20
€32.26
+68.0%
15.1%€42.15€27.14n/a7
Apr ’25€20.20
€30.81
+52.5%
9.3%€34.23€26.77n/a7
Mar ’25€20.80
€30.63
+47.2%
10.0%€34.23€26.77€16.406
Feb ’25€18.60
€26.74
+43.8%
18.9%€33.97€20.04€20.606
Jan ’25€9.80
€22.30
+127.6%
6.4%€23.70€20.04€24.004
Dec ’24€8.50
€22.51
+164.8%
6.7%€24.31€20.27€19.204
Nov ’24€7.90
€22.46
+184.3%
7.7%€24.19€19.69€15.004
Oct ’24€8.50
€22.07
+159.7%
8.4%€24.19€19.69€14.403
Sep ’24€9.35
€20.47
+118.9%
5.2%€22.28€19.49€14.404
Aug ’24€10.30
€20.53
+99.3%
4.1%€21.89€19.62€15.704
Jul ’24€11.00
€20.75
+88.6%
4.7%€22.32€19.62€17.004
Jun ’24€12.70
€19.59
+54.3%
8.4%€21.78€17.19€16.204
May ’24€15.10
€19.45
+28.8%
9.6%€22.09€17.19€19.204
Apr ’24€12.00
€19.31
+60.9%
9.6%€22.09€17.48€20.204
Mar ’24€12.30
€19.17
+55.8%
9.2%€21.95€17.48€20.804
Analyst Price Target
Consensus Narrative from 8 Analysts
€31.71
Fair Value
48.3% undervalued intrinsic discount
8
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/20 07:14
End of Day Share Price 2025/02/26 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

NewAmsterdam Pharma Company N.V. is covered by 13 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Judah FrommerCredit Suisse
Debjit ChattopadhyayGuggenheim Securities, LLC
null nullGuggenheim Securities, LLC